Hepatocellular Carcinoma
2009 and Beyond

Guest Editors
Masatoshi Kudo, Osaka
Okio Hino, Tokyo
Soo-Ryang Kim, Kobe
Hyu-Suk Lee, Seoul

59 figures, 2 in color, and 25 tables, 2008
Disclosure Statement Guest Editors
The guest editors declare that they have no financial conflict of interest.

Disclaimer
The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publisher and the editor(s). The appearance of advertisements in the journal is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Drug Dosage
The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any change in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Introduction

1 Hepatocellular Carcinoma 2009 and Beyond: from the Surveillance to Molecular Targeted Therapy
Kudo, M. (Osaka)

13 Epidemiology of Hepatocellular Carcinoma in Japan and Korea. A Review
Kim, S.R. (Kobe); Kudo, M. (Osaka-Sayama); Hino, O. (Tokyo); Han, K.H.; Chung, Y.H.; Lee, H.S. (Seoul) for the Organizing Committee of Japan-Korea Liver Symposium (JKLS)

17 Experimental Agents Which Inhibit Hepatocarcinogenesis
Yoon, J.-H.; Lee, H.-S. (Seoul)

22 Inhibitory Function of Interferon on Hepatocarcinogenesis
Yano, H. (Kurume)

30 Impact of Interferon Therapy after Curative Treatment of Hepatocellular Carcinoma
Kudo, M. (Osaka-Sayama)

42 Sonazoid-Enhanced Ultrasonography for Diagnosis of Hepatic Malignancies: Comparison with Contrast-Enhanced CT
Hatanaka, K.; Kudo, M.; Minami, Y.; Maekawa, K. (Osaka-Sayama)

48 Imaging of Hepatocellular Carcinoma: Qualitative and Quantitative Analysis of Postvascular Phase Contrast-Enhanced Ultrasonography with Sonazoid. Comparison with Superparamagnetic Iron Oxide Magnetic Resonance Images

55 Intranodular Blood Supply Correlates Well with Biological Malignancy Grade Determined by Tumor Growth Rate in Pathologically Proven Hepatocellular Carcinoma
Kudo, M. (Osaka-Sayama); Tochio, H. (Kobe)

65 Magnetic Resonance Imaging of Hepatocellular Carcinoma
Kaniwatsu, M.; Kondo, H.; Goshima, S.; Tsuge, Y.; Watanabe, H. (Gifu)

72 Magnetic Resonance Imaging of Hepatocellular Carcinoma Using Contrast Media
Kim, M.-J.; Choi, J.-Y.; Chung, Y.E.; Choi, S.Y. (Seoul)
83 Validation of a New Prognostic Staging System for Hepatocellular Carcinoma: A Comparison of the Biomarker-Combined Japan Integrated Staging Score, the Conventional Japan Integrated Staging Score and the BALAD Score

91 PIVKA-II Is the Best Prognostic Predictor in Patients with Hepatocellular Carcinoma after Radiofrequency Ablation Therapy

99 Response Evaluation of Transcatheter Arterial Chemoembolization in Hepatocellular Carcinomas: The Usefulness of Sonazoid-Enhanced Harmonic Sonography

106 Combination Therapy with S-1 and Pegylated Interferon Alpha for Advanced Hepatocellular Carcinoma

114 Systemic Chemotherapy of Hepatocellular Carcinoma – Korean Experience
Lee, H.C. (Seoul)

119 Surgical Treatment of Hepatocellular Carcinoma: Comparison of Resection and Transplantation
Sugawara, Y.; Kokudo, N. (Tokyo)

124 Current Role of Surgery in Treatment of Early Stage Hepatocellular Carcinoma: Resection versus Liver Transplantation
Yi, N.-J.; Suh, K.-S.; Kim, T.; Kim, J.; Shin, W.Y.; Lee, K.-U. (Seoul)

129 Author Index Vol. 75, Suppl. 1, 2008

130 Subject Index Vol. 75, Suppl. 1, 2008